FDA
-
-
-
-
-
-
-
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
-
-
-
-
-
-
-
BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
-
-
-
-
-
-
-
BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
-
-
-
-
-
-
-
BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
-
-
-
-
-
-
-
BioTime (BTX) Announces Updated OpRegen® Phase I/IIa Trial Data
-
-
-
-
-
-
-
Asterias Announces Two Significant Developments for Spinal Cord Injury Program
-
-
-
-
-
-
-
BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
-
251,551 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All